Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

This is a Phase 2, randomized, open-label controlled study to evaluate the efficacy and safety of Ampligen treatment combined with standard of care (SOC) versus SOC alone following First-line therapy in subjects with locally advanced pancreatic adenocarcinoma.